Indegene AI Solutions Strategist – Round 1 Cheat Sheet (Back)

Strengths · Weak Spots & Defenses · Questions to Ask · Watch-Outs — companion to front-side company facts / predicted questions

Strengths to Lead With (reordered 2026-08-03 to Zodiac's weighted rubric — see Rubric Alignment addendum)

[Wt 5] Life Science R&D clinical/regulatory depth: 42 years licensed RPh/RNPh under continuous NRC/FDA oversight; hands-on ICH/CTD content work with Amgen's clinical writers for an FDA NDA submission; J&J MedTech FDA + EU MDR dual compliance; Cardinal Health regulatory compliance across 80+ radiopharmacies. This is the client's highest-weighted criterion — lead here.
[Wt 4] Business acumen: COO (Alliance Mobile Financial, P&L ownership), Executive Director of Innovation (Cardinal Health, $300M+ in contract violation claims won, $2M+ annual MDM savings), $750K annual cost reduction (J&J MedTech AWS migration).
[Wt 4] Customer centricity: nearly the entire career since 2013 is direct, corp-to-corp client-facing consulting through 4Shadow Analytix, not internal-only delivery.
[Wt 4] Technically adept: self-hosted LLM infrastructure (vLLM, Qwen3-32B), multi-cloud (AWS/Azure/GCP), full MLOps stack — breadth beyond what NEXT itself requires.
[Wt 3] GenAI governance: NewsRx's production agentic writing system, zero-fabrication guardrails, HHEM/BERTScore cross-correlation, ALCOA+ audit trail — answers the JD's "source-grounded, traceable, defensible" language, but note this criterion is weighted below the four above it; don't over-invest call time here.
[Wt 2, keep brief] Hands-on medical writing: no literal authorship title — this is explicitly the client's lowest-weighted criterion. State the honest boundary once and move on; it is not the centerpiece.

Gap	Defense
No literal "medical writer" title or personal authorship of protocols/CSRs/IBs. (Client's lowest-weighted criterion, 2/5 — answer briefly, don't over-defend.)	"42 years of licensed clinical documentation practice, hands-on ICH/CTD content work with Amgen's clinical writers, and a production agentic writing system I built and govern at NewsRx — that combination fits what this role actually does better than authorship-only experience would."
No direct hands-on experience with Indegene's own Cortex/NEXT platform.	"I haven't operated Cortex specifically, but I've built and run the same architectural pattern in production — model-agnostic orchestration, source-grounded generation, audit-trail traceability — so this is about learning your configuration, not the underlying discipline."
Global Working Model / frequent client-site travel.	Not a skill gap — a logistics question. Answer honestly and directly based on actual current willingness/constraints; do not overclaim.
Doesn't know the named client account or regulatory framework (FDA/EMA/ICH) this seat serves — Indegene doesn't disclose it publicly.	Reframe as a question to ask them, not a gap to defend (see Q3, right).

Which client account or Strategic Tier engagement does this seat support, and does it report into Sameer Lal's Enterprise Medical Solutions org?
Which specific LLM(s) and RIM/DAM system (Veeva Vault or otherwise) does this engagement run on — Cortex is built to be model-agnostic, so I'd like to know the actual configuration here.
Which regulatory framework does the client operate under — FDA, EMA, ICH, or a combination?
How mature is NEXT's client adoption today — case counts, therapeutic areas, reference clients — beyond the July 2025 launch announcement?
Is this a net-new client stand-up or scaling delivery on an already-running NEXT engagement?
Your July 31 earnings call mentioned enterprise adoption is "measured" even where enthusiasm is real — for this specific engagement, what's been the actual point of resistance: reviewer trust in AI-drafted content, a governance/access-tier dispute, or a terminology-consistency fight with house style?

Vladimir Penkrat is confirmed business/adoption, not technical: AVP/Head of Regulatory Affairs, public speaker on GenAI organizational redesign and client trust (AMWA 2024, RAPS workshops). Expect "how would you get a client's regulatory org to adopt this," not "walk me through your Cortex config." Given his seniority as the required attendee, this round likely carries real decision weight, not just a screen.
Naresh A is unconfirmed and optional — elevated no-show risk. Don't script a persona for him; keep a balanced answer ready that holds up whether the second seat is technical, business, or he doesn't show at all.
Three-tier staffing chain (Zodiac Solutions → Mapout Digital → Indegene) is unusual for a senior embedded strategy role — typically signals surge/delivery capacity against an already-sold program, not a from-scratch practice build. Don't be surprised if the interviewer's framing is narrower/more delivery-focused than the JD's strategic language.
JD's regulatory language ("source-grounded, traceable, consistent, defensible") is generic — does not confirm any specific compliance framework (21 CFR Part 11, ICH M11, etc.) is actually in play. Don't assume; ask.
Indegene's investor materials give more disclosed revenue traction to Tectonic (commercial/marketing-focused) than to NEXT specifically — NEXT may be earlier-stage in actual client deployment than the JD's confident language implies.